Research Article

Screening for a Potential Therapeutic Agent from the Herbal Formula in the 4th Edition of the Chinese National Guidelines for the Initial-Stage Management of COVID-19 via Molecular Docking

Table 4

The chemical compounds with active result from bioassay against respiratory infectious viral activity.

HerbChemical compoundVirus typeMinimal concentrationStudy typeReference

Atractylodes lancea (Thunb.) Dc.Atractylenolide IIIPorcine reproductive and respiratory syndrome virusIC50 = 99.6 µmol/LIn vitro[10]
Citrus reticulata BlancoHesperidinSARS-CoV-2N/AIn silico[11, 12]
Agastache rugosaQuercetinSARS-CoVIC50 = 8.1 ± 0.3 µmIn vitro[13]
Amomum tsaoko Crevost et Lemarie
Ephedra sinica Stapf
Agastache rugosaQuercetinInfluenza A virus H1N1 A/PR/8/34EC50 = 43.1 µmIn vitro[14]
Amomum tsaoko Crevost et Lemarie
Ephedra sinica Stapf
Agastache rugosaQuercetinSARS-CoVIC50 = 23.8 µmIn vitro[15]
Amomum tsaoko Crevost et Lemarie
Ephedra sinica Stapf
Agastache rugosaApigeninInfluenza A virus H1N1 A/PR/8/34IC50 = 31.6 ± 0.9 µmIn vitro[16]
Ephedra sinica Stapf
Agastache rugosaApigeninInfluenza A virus H3N2 A/Jinan/15/90IC50 = 28.9 ± 0.7 µmIn vitro[16]
Ephedra sinica Stapf
Agastache rugosaApigeninInfluenza A virus B/Jiangsu/10/2003IC50 = 45.7 ± 2.3 µmIn vitro[16]
Ephedra sinica Stapf
Amomum tsaoko Crevost et LemarieQuercetin, 3-o-rutinoside (Synonymous rutin)Influenza A virus H1N1IC50 = 34.4 ± 5.0 µmIn vitro[14]
Ephedra sinica Stapf
Amomum tsaoko Crevost et LemarieHirsutrinInfluenza A virus A/swine/OH/511445/2007 H1N1ED50 = 1.2 µmIn vitro and in vivo[17]
Ephedra sinica StapfCosmetinInfluenza A virus H1N1 A/PR/8/34EC50 = 43.0 µmIn vitro[14]
Ephedra sinica StapfVitexinInfluenza A virus H1N1 A/PR/8/34IC50 = 46.5 ± 0.6 µmIn vitro[16]
Ephedra sinica StapfVitexinInfluenza A virus H3N2 A/Jinan/15/90IC50 = 45.1 ± 1.3 µmIn vitro[16]
Ephedra sinica StapfVitexinInfluenza A virus B/Jiangsu/10/2003IC50 = 49.6 ± 3.1 µmIn vitro[16]
Ephedra sinica StapfLuteolinInfluenza A virus H1N1 A/PR/8/34IC50 = 33.7 ± 0.7 µmIn vitro[16]
Ephedra sinica StapfLuteolinInfluenza A virus H3N2 A/Jinan/15/90IC50 = 32.6 ± 0.1 µmIn vitro[16]
Ephedra sinica StapfLuteolinInfluenza A virus B/Jiangsu/10/2003IC50 = 53.3 ± 5.1 µmIn vitro[16]
Ephedra sinica StapfHerbacetinInfluenza A virus H1N1 A/PR/8/34EC50 = 35.0 µmIn vitro[14]
Ephedra sinica StapfKaempferolInfluenza A virus H1N1 A/PR/8/34IC50 = 58.6 ± 0.6 µmIn vitro[16]
Ephedra sinica StapfKaempferolInfluenza A virus H3N2 A/Jinan/15/90IC50 = 38.1 ± 0.3 µmIn vitro[16]
Ephedra sinica StapfKaempferolInfluenza A virus B/Jiangsu/10/2003IC50 = 46.4 ± 0.8 µmIn vitro[16]
Zingiber officinale RoscoeEuxanthoneInfluenza A virus H1N1IC50 = 23.54 ± 3.68 µmIn vitro[18]
Zingiber officinale RoscoeEuxanthoneInfluenza A virus H9N2IC50 = 22.45 ± 3.45 µmIn vitro[18]
Zingiber officinale RoscoeEuxanthoneInfluenza A virus H1N1 swineIC50 = 11.54 ± 0.35 µmIn vitro[18]
Zingiber officinale RoscoeEuxanthoneInfluenza A virus H1N1 (H274Y)IC50 = 13.01 ± 0.41 µmIn vitro[18]

EC50: half maximal effective concentration; IC50: half maximal inhibitory concentration.